Nature Communications (Feb 2021)
Tumour gene expression signature in primary melanoma predicts long-term outcomes
- Manik Garg,
- Dominique-Laurent Couturier,
- Jérémie Nsengimana,
- Nuno A. Fonseca,
- Matthew Wongchenko,
- Yibing Yan,
- Martin Lauss,
- Göran B. Jönsson,
- Julia Newton-Bishop,
- Christine Parkinson,
- Mark R. Middleton,
- D. Timothy Bishop,
- Sarah McDonald,
- Nikki Stefanos,
- John Tadross,
- Ismael A. Vergara,
- Serigne Lo,
- Felicity Newell,
- James S. Wilmott,
- John F. Thompson,
- Georgina V. Long,
- Richard A. Scolyer,
- Pippa Corrie,
- David J. Adams,
- Alvis Brazma,
- Roy Rabbie
Affiliations
- Manik Garg
- European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI)
- Dominique-Laurent Couturier
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way
- Jérémie Nsengimana
- University of Leeds School of Medicine
- Nuno A. Fonseca
- CIBIO/InBIO-Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Rua Padre Armando Quintas
- Matthew Wongchenko
- Oncology Biomarker Development, Genentech Inc.
- Yibing Yan
- Oncology Biomarker Development, Genentech Inc.
- Martin Lauss
- Lund University Cancer Center, Lund University
- Göran B. Jönsson
- Lund University Cancer Center, Lund University
- Julia Newton-Bishop
- University of Leeds School of Medicine
- Christine Parkinson
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust
- Mark R. Middleton
- Oxford NIHR Biomedical Research Centre and Department of Oncology, University of Oxford
- D. Timothy Bishop
- University of Leeds School of Medicine
- Sarah McDonald
- Department of Pathology, Cambridge University Hospitals NHS Foundation Trust
- Nikki Stefanos
- Department of Pathology, Cambridge University Hospitals NHS Foundation Trust
- John Tadross
- Department of Pathology, Cambridge University Hospitals NHS Foundation Trust
- Ismael A. Vergara
- Melanoma Institute Australia, The University of Sydney
- Serigne Lo
- Melanoma Institute Australia, The University of Sydney
- Felicity Newell
- QIMR Berghofer Medical Research Institute
- James S. Wilmott
- Melanoma Institute Australia, The University of Sydney
- John F. Thompson
- Melanoma Institute Australia, The University of Sydney
- Georgina V. Long
- Melanoma Institute Australia, The University of Sydney
- Richard A. Scolyer
- Melanoma Institute Australia, The University of Sydney
- Pippa Corrie
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust
- David J. Adams
- Experimental Cancer Genetics, The Wellcome Sanger Institute
- Alvis Brazma
- European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI)
- Roy Rabbie
- Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust
- DOI
- https://doi.org/10.1038/s41467-021-21207-2
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
The identification of prognostic biomarkers can help stratify cancer patients. Here, the authors apply deep RNA sequencing from primary melanomas coupled with long-term clinical outcome data from a prospective multicentre phase III trial, to develop and validate a 121 metastasis-associated gene signature identifying early-stage melanoma patients at higher risk of metastasis and worse survival.
